Building protected data sharing networks to advance cancer risk assessment and treatment

项目摘要 基因组学和数据分析的进步为准确的风险预测创造了新的机会， 通过跨机构的大规模数据联合，为罕见的癌症提供个性化的医疗治疗。然而 癌症研究经常因缺乏适当的工具来简化临床转移和共享而受阻， 用于癌症研究的患者数据。Globus服务允许安全的数据传输、同步和共享， 大规模的分布式环境。我们在此建议扩展这些服务，使其适合 安全地使用受保护的人类数据。扩展服务将允许临床患者数据的联合 用于准确的癌症风险预测、个性化治疗以及任何其他癌症研究领域。 Globus应用广泛，拥有超过15，000名用户，8，000多个存储系统可通过Globus访问， 包括大多数美国领先的大学和海外的许多网站，以及超过165 PB和250亿 文件传输。生物医学研究人员采用Globus的速度很快，而且正在加速。生物医学 大约30所大学、政府机构和测序中心的研究人员依靠Globus进行 简化数据传输和共享。我们的“Globus Genomics”（GG）整合了银河-Globus-云基因组学 分析系统已被300多名研究人员使用，这些研究人员跨越多个生物医学研究领域， 包括癌症，在超过25个机构分析超过10，000个样本。 我们将开发一个HIPAA Enablement Toolkit，使Globus和其他软件即服务提供商能够 （包括政府补助金）以安全地管理受保护的数据（目标1.1）。我们将通过以下方式扩展Globus安全功能： 实现文件名加密和通过使用用户提供的密钥加密数据，并证明这些 GG和其他服务可以使用新功能来实现弹性，安全，高性能的癌症 基因组学数据分析（目标1.2）。我们将通过开发统一的云计算平台， 存储系统接口（目标2.1）、设计高速传输（目标2.2）和实现搜索， 复制和同步（Aim 2.3），以便 癌症研究人员可以在这些和其他（例如，当地） 计算和存储平台。由此产生的工具将适用于所有癌症类型 光谱研究我们将首先在现有的和新兴的领域内验证和传播这些新技术。 乳腺癌（目标3.1）、血液癌（目标3.2）和胰腺癌（目标3.3）研究网络，然后更广泛地 与癌症研究连续体的合作者（目标3.4）。我们将与合作者密切合作， 用户，以确保我们满足癌症研究界广泛的跨部门需求， 需要传输、共享和分析大型人工数据集。我们将利用广泛的社区外展 通过多种渠道广泛传播我们的技术。

Project Summary Advances in genomics and data analytics create new opportunities for accurate risk prediction and personalized medical treatment for even rare cancers via large-scale data federation across institutions. Yet cancer research is often stymied by a lack of appropriate tools to streamline the transfer and sharing of clinical patient data for cancer research. Globus services permit secure data transfer, synchronization, and sharing in distributed environments at large scale. We propose here to extend these services so that they are appropriate to work securely with protected human data. The extended services will allow federation of clinical patient data for accurate cancer risk prediction, personalized treatment, as well as any other cancer research area. Globus is widely used, with over 15,000 users, more than 8,000 storage systems accessible via Globus, including at most leading US universities and many sites overseas, and more than 165 petabytes and 25 billion files transferred. Adoption of Globus by biomedical researchers has been rapid and is accelerating. Biomedical researchers at ~30 universities, government agencies, and sequencing centers have relied on Globus for streamlined data transfer and sharing. Our “Globus Genomics” (GG) integrated Galaxy-Globus-cloud genomics analysis system has been used by more than 300 researchers across multiple biomedical research domains, including cancer, at over 25 institutions to analyze over 10,000 samples. We will develop a HIPAA Enablement Toolkit that will enable Globus and other software-as-a-service providers (including GG) to manage protected data securely (Aim 1.1). We will extend Globus security features by implementing file name encryption and by encrypting data with user-supplied keys, and demonstrate that these new features can be used by GG and other services to enable elastic, secure, high-performance cancer genomics data analysis (Aim 1.2). We will integrate Globus with major cloud platforms by developing uniform storage system interfaces (Aim 2.1), engineering high-speed transfers (Aim 2.2), and implementing search, replication, and synchronization (Aim 2.3) on AWS, Google, Microsoft, and OpenStack-based clouds, so that cancer researchers can transfer and share data securely and easily among these and other (e.g., local) computing and storage platforms. The resulting tools will be applicable to any cancer type across the cancer research spectrum. We will validate and disseminate these new technologies first within existing and emerging breast (Aim 3.1), blood (Aim 3.2), and pancreatic (Aim 3.3) cancer research networks and then more broadly with collaborators across the cancer research continuum (Aim 3.4). We will work closely with collaborators and users to ensure that we meet the needs of a broad cross-section of the cancer research community that requires transfer, sharing, and analysis of large, human data sets. We will use extensive community outreach through multiple channels to widely disseminate our technologies.